Metabolic & Weight
Tirzepatide
Tirzepatide (dual GLP-1/GIP agonist)
Dual GLP-1 + GIP receptor agonist · most effective weight-loss peptide approved
- FDA Status
- FDA-approved · Mounjaro (T2D) 2022 · Zepbound (obesity) 2023
- Class
- Dual incretin agonist · 39 amino acids · pegylated
- Sequence
- Modified GLP-1 backbone with GIP-targeting substitutions
- Half-life
- ~5 days · once-weekly subcutaneous
Mechanism of action
- Simultaneous activation of GLP-1 and GIP receptors
- GIP-mediated adipocyte function modulation
- Insulinotropic effect amplified vs single-receptor agonists
- Direct hypothalamic appetite suppression
Research areas
- Obesity: SURMOUNT-1 trial showed up to 22.5% body weight reduction at 15 mg
- Type 2 diabetes: SURPASS trials, ~2.4% HbA1c reduction
- NASH and metabolic-associated fatty liver disease
- Cardiovascular outcome trials (SURMOUNT-MMO ongoing)
Evidence and clinical data
Head-to-head superior to semaglutide in SURPASS-2 (greater HbA1c and weight reduction at all doses). Strongest weight-loss data of any approved drug class to date.
Safety profile
Similar safety profile to semaglutide. GI effects predominate. Long-term cardiovascular safety being established in ongoing trials.
Why this peptide is trending in 2026: Surpasses semaglutide in efficacy. Eli Lilly investment in compounded availability and expanded indications. Often cited as the new gold standard for medical weight management.
Educational use only. PeptideAdvance does not sell Tirzepatide, recommend its use, or provide medical advice. The information above is a summary of published research and regulatory status as of April 2026. Some peptides discussed here are not FDA-approved or are restricted under FDA Category 2 — their use outside of authorized clinical research may carry legal and safety implications. Always consult a licensed healthcare professional.